{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:35Z","timestamp":1792828775939,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Gynecological cancer is the most prevalent cancer among women worldwide. We performed a meta-analysis to assess the impact of <jats:sup>18<\/jats:sup>F-FDG PET on the management of patients with recurrent gynecological cancers, including cervical, uterine, and ovarian cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We systematically searched MEDLINE and EMBASE databases for English-language publications. All published studies on the impact of PET scans on the management of patients with recurrent gynecological cancers were reviewed. The proportion of management change (%), defined as the percentage of patients whose management changed after FDG PET to those who underwent FDG PET, was calculated. The data from each study were analyzed using MedCalc Statistical Software version 14.12.0 (MedCalc Software, Ostend, Belgium).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nineteen studies including 6191 patients were eligible for inclusion. The impact of FDG PET scan for detecting recurrence\/metastasis in patients with gynecologic cancer was evaluated using management change rates, ranging from 9.4% to 60.7% with a pooled effect of 42.0% (95% confidence interval [CI], 34.5%\u201349.6%; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 92.9%). In the subtype analysis, FDG PET scanning resulted in changes in the management in 48.5% (95% CI, 37.8%\u201359.3%; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 67.8%) of cervical cancer, 34.7% (95% CI, 33.4%\u201336.0%; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 0%) of uterine cancer, and 40.3% (95% CI, 26.7%\u201354.7%; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 95.2%) of ovarian cancer cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>FDG PET has a significant impact on the restaging of patients with gynecological cancer. These findings suggest that FDG PET should be performed, especially in cases of suspected recurrence\/metastasis in the main gynecologic cancer types, including cervical, ovarian, and uterine cancers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004839","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:08:11Z","timestamp":1695841691000},"page":"945-949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Impact of 18F-FDG PET on the Management in Patients With Recurrent Gynecologic cancer"],"prefix":"10.1097","volume":"48","author":[{"given":"Kyoungjune","family":"Pak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jeon","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ewha Womans University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"bib1-20250621","article-title":"Incidence of gynecologic cancers","volume":"39","year":"2014","journal-title":"US Pharm"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"20170283","DOI":"10.1259\/bjr.20170283","article-title":"The role of 18F-FDG PET CT in common gynaecological malignancies","volume":"90","year":"2017","journal-title":"Br J Radiol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1003465","DOI":"10.3389\/fonc.2022.1003465","article-title":"Meta-analysis of the diagnostic value of 18F-FDG PET\/CT in the recurrence of epithelial ovarian cancer","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MNM.0000000000000026","article-title":"Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis","volume":"35","year":"2014","journal-title":"Nucl Med Commun"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.115.170597","article-title":"High diagnostic value of 18F-FDG PET\/CT in endometrial cancer: systematic review and meta-analysis of the literature","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","year":"1950","journal-title":"Ann Math Stat"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","year":"1986","journal-title":"Control Clin Trials"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","year":"2003","journal-title":"BMJ"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4103\/0972-3919.121966","article-title":"Role of F-18 fluorodeoxyglucose positron emission tomography\/computed tomography in the detection of recurrence in patients with cervical cancer","volume":"28","year":"2013","journal-title":"Indian J Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/IGC.0b013e3182a50537","article-title":"Clinical impact of 2-deoxy-2-[18F]fluoro-d-glucose (FDG)\u2013positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri","volume":"23","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2006.09.009","article-title":"Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence","volume":"104","year":"2007","journal-title":"Gynecol Oncol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cncr.11928","article-title":"Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-d-glucose positron emission tomography","volume":"100","year":"2004","journal-title":"Cancer"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00259-010-1417-1","article-title":"Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2967\/jnumed.108.055046","article-title":"Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET","volume":"49","year":"2008","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2967\/jnumed.112.103911","article-title":"Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2008.01.030","article-title":"Role of PET or PET\/CT in the post-therapy surveillance of uterine sarcoma","volume":"109","year":"2008","journal-title":"Gynecol Oncol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00259-010-1416-2","article-title":"Clinical value of FDG PET\/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET\/CT on patient management?","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00259-006-0260-x","article-title":"Role of [18F]FDG PET\/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings","volume":"34","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00259-013-2610-9","article-title":"Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","article-title":"The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project","volume":"112","year":"2009","journal-title":"Gynecol Oncol"},{"key":"bib21-20250621","first-page":"207","article-title":"18F-FDG PET\/CT in ovarian cancer recurrence: clinical impact, correlation with CECT and CA-125, and prognostic value","volume":"40","year":"2021","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12149-016-1100-0","article-title":"Clinical usefulness of post-treatment FDG PET\/CT in patients with ovarian malignancy","volume":"30","year":"2016","journal-title":"Ann Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00259-008-0776-3","article-title":"Performance of integrated FDG-PET\/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET\/non\u2013contrast-enhanced CT and enhanced CT","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":"Integrated PET\/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer","volume":"34","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","year":"2006","journal-title":"Gynecol Oncol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2007.07.082","article-title":"Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence","volume":"108","year":"2008","journal-title":"Gynecol Oncol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2014.02.008","article-title":"Utility of 18F-FDG PET\/CT in follow-up of patients with low-grade serous carcinoma of the ovary","volume":"133","year":"2014","journal-title":"Gynecol Oncol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MNM.0000000000000775","article-title":"The clinical value of PET and PET\/CT in the diagnosis and management of suspected cervical cancer recurrence","volume":"39","year":"2018","journal-title":"Nucl Med Commun"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.2007.14.5631","article-title":"Impact of positron emission tomography\/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1055\/a-0882-4116","article-title":"Sarcoma of the uterus. Guideline of the DGGG and OEGGG (S2k level, AWMF register number 015\/074, February 2019)","volume":"79","year":"2019","journal-title":"Geburtshilfe Frauenheilkd"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:06Z","timestamp":1750532766000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004839"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004839","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}